Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19

• Päätekijät: Morgan D. McSweeney (Tekijä), Ian Stewart (Tekijä), Zach Richardson (Tekijä), Hyunah Kang (Tekijä), Yoona Park (Tekijä), Cheolmin Kim (Tekijä), Karthik Tiruthani (Tekijä), Whitney Wolf (Tekijä), Alison Schaefer (Tekijä), Priya Kumar (Tekijä), Harendra Aurora (Tekijä), Jeff Hutchins (Tekijä), Jong Moon Cho (Tekijä), Anthony J. Hickey (Tekijä), Soo Young Lee (Tekijä), Samuel K. Lai (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2023-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract The respiratory tract represents the key target for antiviral delivery in early interventions to prevent severe COVID‐19. While neutralizing monoclonal antibodies (mAb) possess considerable efficacy, their current reliance on parenteral dosing necessitates very large doses and places a subs...